已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Immunotherapy for bilateral multiple ground glass opacities: An exploratory study for synchronous multiple primary lung cancer

医学 免疫疗法 腺癌 肺癌 内科学 肿瘤科 不利影响 阿替唑单抗 癌症 彭布罗利珠单抗
作者
Lin Xu,Meiqi Shi,Siwei Wang,Ming Li,Wenda Yin,Jingyuan Zhang,Jun Zhu,Feng Jiang,Wenjia Xia,Ninglei Qiu,Zhi Zhang,Jianfeng Huang,Zhifei Ma,Fanchen Meng,Hongyu Zhu,Guozhang Dong,Jie Wang,Rong Yin
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:13 被引量:9
标识
DOI:10.3389/fimmu.2022.1009621
摘要

Bilateral multiple ground glass opacities (GGOs) are observed in quite a part of patients with early-stage lung adenocarcinoma. For this so-called synchronous multiple primary lung cancer (sMPLC), targeting immune checkpoint is a favorable option in addition to surgical resection. The purpose of this study is to reveal the safety and efficacy of performing immune checkpoint inhibitors (ICIs) on patients with sMPLC and to explore the biomarkers of the efficacy.A total of 21 patients with sMPLC were enrolled and all included cases were pathologically confirmed adenocarcinoma after conducting surgical treatment for unilateral GGOs. ICIs of Sintilimab were then used to target programmed death 1 (200mg i.v., Q3W) for up to 10 cycles. Seven patients of them received the other surgery for contralateral GGOs, and multiomics assessments, including neoantigens, somatic mutations, and methylated loci, were further performed to investigate potential biomarkers.Grade 1 or 2 treatment-related adverse events (AEs) occurred in most of the patients (12/21, 57.1%), and one subject withdrawn for grade 3 AEs. For the seven patients underwent twice surgeries, twelve and thirteen GGOs were achieved before and after the use of ICIs separately, and a favorable efficacy was observed among six lesions after immunotherapy (> 50% pathologic tumor regression). Tumor infiltration T-cell and B-cell were further shown to be associated with the biological activity of ICIs. According to mechanism-based multiomics analyses, MUC19- and PCDHB5- mutations were indicated to correlate with a favorable prognosis of sMPLC underwent immunotherapy, and our results suggested that immunogenetic mutation and associated promoter methylation could provide a quantitative explanation for the pathologic response of GGOs.Our study provides evidence that the use of ICIs contributed favorable efficacy and safety to patients with sMPLC. Immune infiltration and immunogenic biomarkers are revealed to be implications of performing ICIs on sMPLC. These preliminary findings exhibit the prospects in performing neoadjuvant or adjuvant immunotherapies on patients with sMPLC.https://www.chictr.org.cn/showproj.aspx?proj=36878, identifier ChiCTR1900022159.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fan完成签到,获得积分10
1秒前
周思完成签到,获得积分10
1秒前
huahuahua发布了新的文献求助10
2秒前
土土桔子糖完成签到 ,获得积分10
2秒前
4秒前
6秒前
6秒前
6秒前
6秒前
6秒前
温婉的灵阳完成签到 ,获得积分10
7秒前
konnie完成签到 ,获得积分10
7秒前
8秒前
8秒前
9秒前
mont发布了新的文献求助20
9秒前
mont发布了新的文献求助30
9秒前
mont发布了新的文献求助10
9秒前
mont发布了新的文献求助10
10秒前
mont发布了新的文献求助10
10秒前
小小心愿发布了新的文献求助10
12秒前
我是谁完成签到 ,获得积分10
12秒前
mont发布了新的文献求助10
12秒前
111完成签到,获得积分10
12秒前
大个的应助被花海采纳,获得10
13秒前
mont发布了新的文献求助10
13秒前
mont发布了新的文献求助20
13秒前
Sora1998完成签到 ,获得积分10
14秒前
mont发布了新的文献求助10
14秒前
mont发布了新的文献求助10
14秒前
14秒前
热情毛巾完成签到,获得积分10
15秒前
mont发布了新的文献求助10
16秒前
16秒前
mont发布了新的文献求助10
16秒前
mont发布了新的文献求助10
16秒前
17秒前
mont发布了新的文献求助10
17秒前
mont发布了新的文献求助10
18秒前
Young完成签到 ,获得积分0
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189992
求助须知:如何正确求助?哪些是违规求助? 9577153
关于积分的说明 21851712
捐赠科研通 7788038
什么是DOI,文献DOI怎么找? 3435863
关于科研通互助平台的介绍 2559910
邀请新用户注册赠送积分活动 2482735